Company intelligence / Profile preview

UNIR

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Unir Therapeutics is a biotechnology company focused on developing novel small molecule therapies for oncology and ophthalmology. The company's primary research centers on the modulation of the hypoxia-inducible factor (HIF) pathway, which plays a critical role in tumor growth and pathological angiogenesis. By targeting HIF-1 alpha and its downstream effectors like VEGF, Unir aims to provide more effective treatments for resistant solid tumors and vision-threatening vascular diseases. Their pipeline is currently in the pre-clinical stage, with a focus on optimizing lead compounds for clinical entry.

Therapeutic areas: OncologyOphthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on UNIR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UNIR.

Explore the full profile